Dearborn Partners LLC Invests $1.72 Million in Zoetis Inc. $ZTS

Dearborn Partners LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 23,988 shares of the company’s stock, valued at approximately $1,724,000.

Several other institutional investors also recently added to or reduced their stakes in ZTS. University of Texas Texas AM Investment Management Co. bought a new position in Zoetis during the second quarter valued at about $25,000. Dunhill Financial LLC lifted its position in shares of Zoetis by 519.3% in the 2nd quarter. Dunhill Financial LLC now owns 353 shares of the company’s stock worth $25,000 after acquiring an additional 296 shares during the period. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the 1st quarter worth approximately $28,000. Finally, Root Financial Partners LLC increased its position in shares of Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares during the period. 92.80% of the stock is owned by institutional investors.

Zoetis Price Performance

ZTS opened at $74.99 on Friday. Zoetis Inc. has a one year low of $71.00 and a one year high of $156.49. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The company’s 50 day simple moving average is $75.59 and its 200-day simple moving average is $95.75. The stock has a market capitalization of $30.99 billion, a P/E ratio of 12.35, a price-to-earnings-growth ratio of 1.81 and a beta of 0.74.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter last year, the business earned $1.76 earnings per share. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

ZTS has been the subject of a number of recent research reports. JPMorgan Chase & Co. dropped their price objective on shares of Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. Cantor Fitzgerald set a $94.00 target price on shares of Zoetis in a research report on Tuesday. HSBC lowered their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Wall Street Zen cut shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, Stifel Nicolaus decreased their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating on the stock in a report on Thursday, August 20th. Eight investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $107.43.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.